Table 1.
Baseline characteristics of patients in the overall population and stratified by treatment.
| Baseline Characteristics | (n = 177) |
|---|---|
| Age | |
| Median (min/max) | 63 (38–92) |
| ≤65 y | 103 (58.2%) |
| >65 y | 74 (41.8%) |
| Menopausal status | |
| Postmenopause | 152 (85.9%) |
| Pre/perimenopause | 25 (14.1%) |
| BMI | |
| ≤25 | 90 (50.8%) |
| >25 | 87 (49.2%) |
| Previous hormonal therapy (HT) | |
| No | 42 (23.7%) |
| Yes | 135 (76.3%) |
| Prior aromatase inhibitor (from the total number of patients receiving HT) | |
| No | 33 (24.4%) |
| Yes | 102 (75.6%) |
| Prior adjuvant chemotherapy | |
| No | 106 (59.9%) |
| Yes | 71 (40.1%) |
| ER status (positive if the value ≥ 10%) | |
| Positive | 175 (98.9%) |
| Negative | 2 (1.1%) |
| PgR status (positive if the value ≥ 10%) | |
| Positive | 139 (78.5%) |
| Negative | 38 (21.5%) |
| Previous lines | |
| First line | 95 (53.7%) |
| ≥2 lines | 82 (46.3%) |
| Metastatic site | |
| Bone only | 45 (25.4%) |
| Visceral | 67 (37.9%) |
| Other | 65 (36.7%) |
| Organs involved, N° | |
| 1 | 75 (42.4%) |
| 2 | 73 (41.2%) |
| ≥3 | 29 (16.4%) |
| Neutropenia | |
| Absent | 79 (44.6%) |
| Present | 98 (55.4%) |
| Ki67 (%) | |
| Median (min/max) | 20 (0–80) |
| <20% | 85 (48.0%) |
| ≥20% | 92 (52.0%) |
| HT | |
| Fulvestrant | 111 (62.7%) |
| Letrozole | 66 (37.3%) |
| Grading | |
| 1 | 3 (1.9%) |
| 2 | 98 (62.8%) |
| 3 | 55 (35.3%) |
| Missing/not known | 21 |